Sermorelin,GHRP-6，GHRP-2
A combination of growth hormone (GH) releasing peptides can lead to tremendousincreases in GH levels, but such a process generally only requires a growth hormonereleasing hormone (GHRH) analogue like sermorelin and a growth hormone secretagogue/ghrelin analogue like GHRP-2 or GHRP-6. Combining all three isn’t likely tocause a proportionally greater increase in GH hormone levels, but are other reasons toutilize such a combination.
Sermorelin is an excellent GHRH analogue with strong GH releasing action and very fewoff-target effects. in addition., the peptide has been found in animal studies to improveheart health, increase bone density, improve renal function, and possibly even fight off theeffects of dementia. GHRP-2 not only helps to build muscle, but has been shown toenhance muscle structure as well[1]-[3]. lt is also a strong appetite stimulant, improvesheart function, boosts immune function, reduces pain perception, and benefits sleepquality[4]-[10]. GHRP-6 has been shown to protect brain tissue, enhance memory, boostwound repair, and modulate reward-seeking behavior[11]-[21].
The above list of effects demonstrates both common overlap as well as complimentary features for the peptides above. By combining a GHRH analogue and a ghrelin analogue.maximal growth hormone release is achieved. By combining all three peptides in thecorrect way (e.g. alternating GHRP-6 with GHRP-2 dosing), it is possible to also amplifythe peptides’ secondary effects and achieve additional benefits such as enhanced bonedeposition, improved brain protection, and more.
Article Author
The above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Loganholds a doctorate degree from Case Western Reserve University School of Medicine anda B.S. in molecular biology.
Scientific Journa Author
Richard F. Walker, Ph.D, R.Ph, lead author of A better approach to management of adult-.onset growth hormone insufficiency?”, received a BS in pharmacy from RutgersUniversity, a MS in Biochemistry from New Mexico State University and a PhD in aphysiology from Rutgers University. He holds postdoctoral fellowships inneuroendocrinology and neuropharmacology at Duke University College of Medicine(Center for the Study of Aging and Human Development) and the University of California, Berkeley, respectively.
Richard F. Walker, Ph.D, R.Ph is being referenced as one of the leading scientists involved in the research and development of Sermorelin. In no way is this doctor/scientistendorsing or advocating the purchase, sale, or use of this product for any reason. Thereis no affiliation or relationship, implied or otherwise, between PEPTIDE GURUS and thisdoctor. The purpose of citing the doctor is to acknowledge, recognize, and credit theexhaustive research and development efforts conducted by the scientists studying thispeptide. Richard F. Walker, Ph.D, R.Ph is listed in [22 ]under the referenced citations.
Resources
1.R. Hu et al., “Effects of GHRP-2 and Cysteamine Administration on GrowthPerformance, Somatotropic Axis Hormone and Muscle Protein Deposition in Yaks(Bos grunniens) with Growth Retardation,” PloS One, vol. 11, no.2, p.e01494612016.
2.D. Yamamoto et al., “GHRP-2, a GHS-R agonist, directly acts on myocytes toattenuate the dexamethasone-induced expressions of muscle-specific ubiquitinligases, Atrogin-1 and MuRF1,” Life Sci., vol.82,no.9-10, pp.460-466, Feb2008.[PubMed]
3.L.T. Phung et al., “The effects of growth hormone-releasing peptide-2 (GHRP-2)on the release of growth hormone and growth performance in swine,” Domest.Anim.Endocrinol., vol.18, no.3, pp.279-291,Apr.2000.[PubMed]
4.B.Laferrère,C.Abraham,C.D.Russell, and C.Y.Bowers, “Growth hormonereleasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men,J.Clin.Endocrinol. Metab., vol.90, no.2, pp.611-614, Feb.2005.[PubMed]
5.B. Laferrère,A. B. Hart, and C.Y. Bowers, “Obese subjects respond to thestimulatory effect of the ghrelin agonist growth hormone-releasing peptide-2 onfood intake,”Obes. Silver Spring Md, vol.14,no.6,pp.1056-1063, Jun.2006[PMC]
6.G. Muccioli et al., “Growth hormone-releasing peptides and the cardiovascularsystem,”Ann.Endocrinol., vol.61,no.1, pp.27-31, Feb.2000.[PubMed]
7.V. Bodart et al., “ldentification and characterization of a new growth hormonereleasing peptide receptor in the heart,” Circ.Res., vol.85,no.9, pp.796-802Oct.1999.[PubMed]
8.D. D. Taub, W. J. Murphy, and D.L. Longo, “Rejuvenation of the aging thymus:growth hormone-mediated and ghrelin-mediated signaling pathways,” Curr. Opin.Pharmacol.,vol.10,no.4,pp.408-424,Aug.2010.[PubMed]
9.G. Copinschi et al., “Prolonged oral treatment with MK-677, a novel growthhormone secretagogue, improves sleep quality in man,” Neuroendocrinology, vol.66,no.4, pp.278-286, Oct. 1997.[PubMed]
10.P. Zeng et al., “Ghrelin receptor agonist, GHRP-2, produces antinociceptive effectsat the supraspinal level via the opioid receptor in mice,” Peptides, vol. 55, pp. 103-109, May 2014.[PubMed]
11.C.-C. Huang, D. Chou, C.-M. Yeh, and K.-S. Hsu,“Acute food deprivation enhances fear extinction but inhibits long-term depression in the lateral amygdalavia ghrelin signaling,”Neuropharmacology, vol.101, pp.36-45, Feb.2016.[PubMed]
12.S. Beheshti and S. Shahrokhi, “Blocking the ghrelin receptor type 1a in the ratbrain impairs memory encoding,”Neuropeptides, vol.52,pp.97-102, Aug.2015.
13.K. Tóth, K. László, and L. Lénárd, “Role of intraamygdaloid acylated-ghrelin in3spatial learning,” Brain Res. Bull., vol. 81,no.1, pp.33-37, Jan.2010.[PubMed]
14.N.Subirós et al.. “Assessment of dose-effect and therapeutic time window inpreclinical studies of rhEGF and GHRP-6 coadministration for stroke therapy,Neurol.Res., vol.38, no.3, pp.187-195, Mar.2016.[PubMed]
15.S. J. Spencer, A. A. Miller, and Z. B. Andrews, “The Role of Ghrelin inNeuroprotection after lschemic Brain Injury,” Brain Sci., vol. 3, no. 1, pp. 344-359Mar.2013.[PMC]
16.Y. Suda et al., “Down-regulation of ghrelin receptors on dopaminergic neurons inthe substantia nigra contributes to Parkinson’s disease-like motor dysfunction,Mol. Brain, vol.11,no.1,p.6,20 2018.[BMC]
17.Y. Mendoza Marí et al., “Growth Hormone-Releasing Peptide 6 Enhances theHealing Process and lmproves the Esthetic Outcome of the Wounds,” PlasticSurgery International, 2016.[Online]. Available:https://www.hindawi.com/journals/psi2016/4361702/.[Accessed: 23-May-2019][PMC]
18.M. FernÃández-Mayola et al., “Growth hormone-releasing peptide 6 preventscutaneous hypertrophic scarring: early mechanistic data from a proteome study,Int. Wound J., vol.15,no.4, pp.538-546,Aug.2018.[PubMed]
19.J. Berlanga et al., “Growth-hormone-releasing peptide 6 (GHRP6) prevents oxidantcytotoxicity and reduces myocardial necrosis in a model of acute myocardialinfarction,”Clin.Sci.Lond.Engl.1979,vol.112,no.4,pp.241-250,Feb.2007[PubMed]
20.L. Hyland et al., “Central ghrelin receptor stimulation modulates sex motivation inmale rats in a site dependent manner,” Horm. Behav., vol. 97, pp.56-66, 2018[Science Direct]
21.H.-J. Huang et al., “The protective effects of Ghrelin/GHSR on hippocampalneurogenesis in CUMS mice,” Neuropharmacology, May 2019. [PubMed]
22.R. F. Walker, “Sermorelin: A better approach to management of adult-onset growthhormone insufficiency?,”Clin.Interv.Aging, vol. 1, no.4, pp.307-308, Dec. 2006.[PubMed]
ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE AREFOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.
The products offered on this website are furnished for in-vitro studies only. in-vitro studies(Latin: in glass) are performed outside of the body. These products are not medicines ordrugs and have not been approved by the FDA to prevent, treat or cure any medicalcondition, ailment or disease. Bodily introduction of any kind into humans or animals isstrictly forbidden by law.
